---
title: "Pharma Pulse 2/6/25: Properly Preparing for Tariffs, Long Term Costs of Major Menopause Misconceptions & more"
date: "2025-02-06 19:00:00"
summary: "Properly Preparing for Tariffs and Other Supply Chain ObstaclesIn the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, shares how the imposed/pending trade tariffs impact pharma manufacturers.The Long Term Cost of Major Menopause MisconceptionsAn overview of menopause taboo,..."
categories:
  - "pharmexec"
lang:
  - "en"
translations:
  - "en"
tags:
  - "pharmexec"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

[**Properly Preparing for Tariffs and Other Supply Chain Obstacles**](https://www.pharmaceuticalcommerce.com/view/properly-preparing-for-tariffs-supply-chain-obstacles)

In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, shares how the imposed/pending trade tariffs impact pharma manufacturers.

[**The Long Term Cost of Major Menopause Misconceptions**](https://www.managedhealthcareexecutive.com/view/the-long-term-cost-of-major-menopause-misconceptions)

An overview of menopause taboo, the lingering effects of the Women’s Health Initiative study and what employers can do support their menopausal workers, according to Stephanie Faubion, MD, director of the Mayo Clinic’s Center for Women’s Health and medical director of The Menopause Society.

[**Jim Chanos Says Biggest Risk for Markets Is DeepSeek-Like Event**](https://www.bloomberg.com/news/articles/2025-02-05/jim-chanos-says-biggest-risk-for-markets-is-deepseek-like-event)

Legendary short seller Jim Chanos says no one can see the biggest risks facing US markets over the next six to 12 months — because the challenges are going to be unpredictable events, like last month’s DeepSeek collapse that wiped out roughly $1 trillion in market value from US stocks.

[**Flatiron Health and Exact Sciences Partner to Advance Clinical Evidence Generation for Molecular Residual Disease Testing**](https://www.businesswire.com/news/home/20250205984500/en)

Flatiron Health and Exact Sciences are entering a strategic partnership aimed at accelerating clinical evidence generation for Exact Sciences’ molecular residual disease test, OncodetectTM. The partnership leverages Flatiron’s clinical research platform to study a broad range of solid tumor types. Their first patient is already enrolled.

[**Spencer Stuart on LinkedIn**](https://www.linkedin.com/feed/update/urn:li:activity:7292955904566566912/?actorCompanyId=3574274)

Claudius A. Hildebrand sat down with [*Pharmaceutical Executive*](https://www.linkedin.com/company/pharmaceutical-executive/) to offer his advice for current and aspiring CEOs in biopharma.

Learn more: <https://bit.ly/3CsjMkb>

*Have news you want us to share in Pharma Pulse? Reach out to Editor [Miranda Schmalfuhs](mailto:mschmalfuhs@mjhlifesciences.com)*

[pharmexec](https://www.pharmexec.com/view/pharma-pulse-2-6-25-)
